The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
GDC-1261 and INR731 enter phase 1, but how do they act?
The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
Could RO7851624, newly into clinical trials, be RG6735?
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
